{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:17:38Z","timestamp":1791605858505,"version":"4.3.4"},"reference-count":31,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:p>Obesity is a prevalent disease that also contributes to the incidence and severity of many other chronic diseases and health conditions. Treatment approaches include lifestyle intervention, bariatric surgery, and pharmacological approaches, with glucagon-like peptide 1 (GLP-1) receptor agonists approved specifically for weight loss having changed the treatment landscape significantly in the last 5 years. Targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor may enhance the metabolic benefits of GLP-1 receptor agonism. These beneficial effects are seen with both GIP receptor antagonism and GIP receptor agonism, although the mechanisms underlying this apparent paradox remain unknown. Here, we summarize the physiologic, genetic, and clinical evidence for pursuing GIP receptor antagonism to achieve metabolic and weight benefits. Both global and central nervous system knockout of GIP receptors protects mice fed a high-fat diet from obesity and insulin resistance. Genome-wide association studies in humans support this notion, correlating lower BMI with GIP receptor genetic variants with reduced function. Pharmacologic approaches in mice and monkeys confirm that GIP receptor antagonism enhances GLP-1\u2013induced weight reduction and other metabolic benefits, and a phase 1 study provides proof of principle that beneficial effects extend to humans. GIP receptor antagonism may represent an important new mechanism to expand the treatment options available to individuals living with obesity.<\/jats:p>","DOI":"10.2337\/dbi24-0027","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T09:01:59Z","timestamp":1750064519000},"page":"1334-1338","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":14,"title":["GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale"],"prefix":"10.2337","volume":"74","author":[{"given":"Mette Marie","family":"Rosenkilde","sequence":"first","affiliation":[{"name":"Molecular and Translational Pharmacology, Department of Biomedical Sciences, University of Copenhagen 1 , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothis Thomas","family":"George","sequence":"additional","affiliation":[{"name":"Amgen Office of the Chief Medical Officer 2 , Amgen, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle M.","family":"V\u00e9niant","sequence":"additional","affiliation":[{"name":"Amgen Research Department of Cardiometabolic Disorders 3 , Amgen, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-3805","authenticated-orcid":false,"given":"Jens Juul","family":"Holst","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism, Department of Biomedical Sciences, University of Copenhagen 4 , Copenhagen, Denmark"},{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen 5 , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"2026061114071627000_B1","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"2026061114071627000_B2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"2026061114071627000_B3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat Metab"},{"key":"2026061114071627000_B4","doi-asserted-by":"crossref","first-page":"102006","DOI":"10.1016\/j.molmet.2024.102006","article-title":"AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys","volume":"88","author":"Jensen","year":"2024","journal-title":"Mol Metab"},{"key":"2026061114071627000_B5","doi-asserted-by":"crossref","first-page":"170276","DOI":"10.1016\/j.peptides.2020.170276","article-title":"The early history of GIP 1969-2000: from enterogastrone to major metabolic hormone","volume":"125","author":"Marks","year":"2020","journal-title":"Peptides"},{"key":"2026061114071627000_B6","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat Med"},{"key":"2026061114071627000_B7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.2040-1124.2011.00143.x","article-title":"Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance","volume":"3","author":"Yamane","year":"2012","journal-title":"J Diabetes Investig"},{"key":"2026061114071627000_B8","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/oby.2008.393","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) stimulates transepithelial glucose transport","volume":"16","author":"Singh","year":"2008","journal-title":"Obesity (Silver Spring)"},{"key":"2026061114071627000_B9","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2337\/db17-0480","article-title":"The gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor","volume":"66","author":"Asmar","year":"2017","journal-title":"Diabetes"},{"key":"2026061114071627000_B10","doi-asserted-by":"crossref","first-page":"E224","DOI":"10.1152\/ajpendo.00347.2016","article-title":"Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response","volume":"312","author":"Thondam","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026061114071627000_B11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.686","article-title":"Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index","volume":"42","author":"Speliotes","year":"2010","journal-title":"Nat Genet"},{"key":"2026061114071627000_B12","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s42255-024-01061-4","article-title":"Characterization of genetic variants of GIPR reveals a contribution of \u03b2-arrestin to metabolic phenotypes","volume":"6","author":"Kizilkaya","year":"2024","journal-title":"Nat Metab"},{"key":"2026061114071627000_B13","doi-asserted-by":"crossref","first-page":"e140532","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"2026061114071627000_B14","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1038\/s41467-020-18751-8","article-title":"Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism","volume":"11","author":"Killion","year":"2020","journal-title":"Nat Commun"},{"key":"2026061114071627000_B15","doi-asserted-by":"crossref","first-page":"44632","DOI":"10.1074\/jbc.M111.311779","article-title":"Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain","volume":"286","author":"Ugleholdt","year":"2011","journal-title":"J Biol Chem"},{"key":"2026061114071627000_B16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm.3997","article-title":"TCF1 links GIPR signaling to the control of beta cell function and survival","volume":"22","author":"Campbell","year":"2016","journal-title":"Nat Med"},{"key":"2026061114071627000_B17","doi-asserted-by":"crossref","first-page":"eaat3392","DOI":"10.1126\/scitranslmed.aat3392","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","volume":"10","author":"Killion","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026061114071627000_B18","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metab"},{"key":"2026061114071627000_B19","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nat Metab"},{"key":"2026061114071627000_B20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.npep.2003.09.002","article-title":"Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?","volume":"37","author":"Gault","year":"2003","journal-title":"Neuropeptides"},{"key":"2026061114071627000_B21","article-title":"Altered desensitization and internalization patterns of rodent versus human glucose-dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge","author":"Gasbjerg","year":"2024","journal-title":"Br J Pharmacol."},{"key":"2026061114071627000_B22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/osp4.164","article-title":"Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice","volume":"4","author":"Nakamura","year":"2018","journal-title":"Obes Sci Pract"},{"key":"2026061114071627000_B23","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1111\/bph.15894","article-title":"Glucose-dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat diet-fed mice","volume":"179","author":"Boer","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2026061114071627000_B24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2018.12.001","article-title":"Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism","volume":"20","author":"Mroz","year":"2019","journal-title":"Mol Metab"},{"key":"2026061114071627000_B25","doi-asserted-by":"crossref","first-page":"101638","DOI":"10.1016\/j.molmet.2022.101638","article-title":"Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems","volume":"66","author":"Yang","year":"2022","journal-title":"Mol Metab"},{"key":"2026061114071627000_B26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.molmet.2019.11.018","article-title":"Pharmacological antagonism of the incretin system protects against diet-induced obesity","volume":"32","author":"Svendsen","year":"2020","journal-title":"Mol Metab"},{"key":"2026061114071627000_B27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"H\u00f8jberg","year":"2009","journal-title":"Diabetologia"},{"key":"2026061114071627000_B28","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat Commun"},{"key":"2026061114071627000_B29","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.2337\/db17-1385","article-title":"Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons","volume":"67","author":"Adams","year":"2018","journal-title":"Diabetes"},{"key":"2026061114071627000_B30","doi-asserted-by":"crossref","first-page":"100263","DOI":"10.1016\/j.xcrm.2021.100263","article-title":"GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys","volume":"2","author":"Lu","year":"2021","journal-title":"Cell Rep Med"},{"key":"2026061114071627000_B31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2337\/dc19-0578","article-title":"No acute effects of exogenous glucose-dependent insulinotropic polypeptide on energy intake, appetite, or energy expenditure when added to treatment with a long-acting glucagon-like peptide 1 receptor agonist in men with type 2 diabetes","volume":"43","author":"Bergmann","year":"2020","journal-title":"Diabetes Care"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/74\/8\/1334\/823477\/dbi240027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/74\/8\/1334\/823477\/dbi240027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:07:28Z","timestamp":1781201248000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/74\/8\/1334\/160595\/GIP-Receptor-Antagonists-in-the-Pharmacotherapy-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,6,16]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dbi24-0027","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]}}}